-transparent.png){kind=logo}
Among the 95 cases of ovarian cancer treated by us between May, 1975 and August, 1978, only 33 were suitable for complete resection. The remaining 62 cases underwent incomplete resection, followed by F.Q.C. combination chemotherapy (1-(2-tetrahydrofuryl)-5-fluorouracil, carbazilquinone, cytosine arabinoside); 54.8% showed an antitumor response. The median survival time of the responders was 13.2 months, whereas it was 7.4 months for the non-responders. The survival rate after 24 months, however, was 13% and 4%, respectively. Side effects of the drugs, including leucopenia, thrombocytopenia, nausea and vomiting, were found in roughly one half of the cases.
Related Publications
A Yajima, and
H Higashiiwai, and
A Sato, and
M Watanabe, and
T Mori, and
M Suzuki, and
T Hanyu, and
K Suzuki, and
H Kinii, and
T Moritsuka, and
N Igarashi, and
M Nakano, and
K Nagasawa, and
S Sato
September 1990,
Cancer treatment reviews,
A Yajima, and
H Higashiiwai, and
A Sato, and
M Watanabe, and
T Mori, and
M Suzuki, and
T Hanyu, and
K Suzuki, and
H Kinii, and
T Moritsuka, and
N Igarashi, and
M Nakano, and
K Nagasawa, and
S Sato
February 1992,
Seminars in oncology,
A Yajima, and
H Higashiiwai, and
A Sato, and
M Watanabe, and
T Mori, and
M Suzuki, and
T Hanyu, and
K Suzuki, and
H Kinii, and
T Moritsuka, and
N Igarashi, and
M Nakano, and
K Nagasawa, and
S Sato
July 1986,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A Yajima, and
H Higashiiwai, and
A Sato, and
M Watanabe, and
T Mori, and
M Suzuki, and
T Hanyu, and
K Suzuki, and
H Kinii, and
T Moritsuka, and
N Igarashi, and
M Nakano, and
K Nagasawa, and
S Sato
October 1986,
Tumori,
A Yajima, and
H Higashiiwai, and
A Sato, and
M Watanabe, and
T Mori, and
M Suzuki, and
T Hanyu, and
K Suzuki, and
H Kinii, and
T Moritsuka, and
N Igarashi, and
M Nakano, and
K Nagasawa, and
S Sato
November 1987,
Cancer,
A Yajima, and
H Higashiiwai, and
A Sato, and
M Watanabe, and
T Mori, and
M Suzuki, and
T Hanyu, and
K Suzuki, and
H Kinii, and
T Moritsuka, and
N Igarashi, and
M Nakano, and
K Nagasawa, and
S Sato
April 2007,
Bulletin du cancer,
A Yajima, and
H Higashiiwai, and
A Sato, and
M Watanabe, and
T Mori, and
M Suzuki, and
T Hanyu, and
K Suzuki, and
H Kinii, and
T Moritsuka, and
N Igarashi, and
M Nakano, and
K Nagasawa, and
S Sato
January 1992,
BMJ (Clinical research ed.),
A Yajima, and
H Higashiiwai, and
A Sato, and
M Watanabe, and
T Mori, and
M Suzuki, and
T Hanyu, and
K Suzuki, and
H Kinii, and
T Moritsuka, and
N Igarashi, and
M Nakano, and
K Nagasawa, and
S Sato
January 1984,
Journal of cancer research and clinical oncology,
A Yajima, and
H Higashiiwai, and
A Sato, and
M Watanabe, and
T Mori, and
M Suzuki, and
T Hanyu, and
K Suzuki, and
H Kinii, and
T Moritsuka, and
N Igarashi, and
M Nakano, and
K Nagasawa, and
S Sato
November 1991,
BMJ (Clinical research ed.),
A Yajima, and
H Higashiiwai, and
A Sato, and
M Watanabe, and
T Mori, and
M Suzuki, and
T Hanyu, and
K Suzuki, and
H Kinii, and
T Moritsuka, and
N Igarashi, and
M Nakano, and
K Nagasawa, and
S Sato
October 1975,
National Cancer Institute monograph,
